“Anakinra, a recombinant human IL-1 receptor antagonist, in clinical practice. Outcome in 60 patients with severe rheumatoid arthritis”, Reumatismo, vol. 59, no. 1, pp. 32–37, Mar. 2007, doi: 10.4081/reumatismo.2007.32.